Despite all the advances the oncology community has seen since 1987 when Eisai came to America, there are still too many people living with cancer, and too many unmet needs remain. That’s why we let the science drive us to new approaches that accelerate progress in oncology, even if it means pursuing breakthroughs in challenging areas unexplored by other companies. Behind that work is our grounding philosophy rooted in empathy, a concept we call human health care (hhc). Our commitment to hhc means that we always prioritize patients and their families above all else. We do what it takes to find the potential in the seemingly impossible, because transformative cancer solutions simply can’t wait.
ONCOLOGY RESEARCH AT EISAI
WE TAKE ON OUR WORK WITH RESILIENCE, CONVICTION AND INTENTION.
-
RESILIENCE
Our quest to find a novel solution
We searched far and wide to find a breakthrough therapy with the potential to help some cancer patients live longer. Our scientists discovered an organic compound found in the ocean and perfected a unique chemical reaction to synthesize it.
WATCH OUR VIDEO TO LEARN HOW A SEA SPONGE
FOUND OFF THE COAST OF JAPAN LED TO THE
CREATION OF A CANCER TREATMENT.A video thumbnail showing a graphic of a partially submersed view of the ocean, with the Eisai logo floating on the surface. Below the surface are coral reefs and fish. Click here for Prescribing Information -
CONVICTION
Our relentless pursuit to develop a targeted therapy
When we set out to explore angiogenesis and potential therapeutic applications in 1991, we envisioned the promise of targeted anticancer therapies and were driven by the aim to maximize for patients the benefits that the scientific community hoped they would provide. As our research progressed, we concentrated on diseases with poor prognoses and limited treatment options. Rather than rushing to be first to market, we stayed true to our vision and prioritized how the compound would bind to certain targets implicated in the pathogenesis of the cancer, including its potential to minimize mechanisms of escape and resistance. This led us to create a targeted anticancer agent.
-
INTENTION
Achieving more for patients through collaboration
We’ve made it our mission to get transformative medicines to those who need them the most, and we forge the most effective collaborations to help expedite our mission. With the hope of reaching more patients in need, we are investigating our targeted agent (a multi-receptor tyrosine kinase inhibitor) in combination with an immuno-oncology therapeutic, Merck’s anti-PD-1 therapy. To date, numerous trials have been initiated under our LEAP clinical program, which is evaluating the combination across multiple tumor types.
Latest News
Read the latest on how we’re helping people living with cancer.
Press Release
JOIN OUR TEAM
LOOKING FOR A TEAM ENVIRONMENT WHERE YOU’LL BE
CHALLENGED AND INSPIRED TO BREAKTHROUGH?
Join us in our commitment to human
health care—our mission to make a
difference in the lives of patients and
people worldwide
